Share This Page
Drug Price Trends for NDC 00536-1047
✉ Email this page to a colleague
Average Pharmacy Cost for 00536-1047
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SODIUM BICARB 650 MG TABLET | 00536-1047-10 | 0.01291 | EACH | 2025-11-19 |
| SODIUM BICARB 650 MG TABLET | 00536-1047-10 | 0.01281 | EACH | 2025-10-22 |
| SODIUM BICARB 650 MG TABLET | 00536-1047-10 | 0.01278 | EACH | 2025-09-17 |
| SODIUM BICARB 650 MG TABLET | 00536-1047-10 | 0.01301 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00536-1047
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00536-1047
Introduction
The pharmaceutical landscape surrounding NDC 00536-1047 is shaped by multiple factors—regulatory status, market demand, competitive dynamics, pricing strategies, and healthcare policies. As a pivotal component within its therapeutic class, this drug's market performance warrants comprehensive analysis to inform stakeholders ranging from manufacturers to healthcare providers and payers.
Product Overview
NDC 00536-1047 is identified as a proprietary medication manufactured by [Manufacturer Name], primarily indicated for [Therapeutic Indication], including conditions such as [specific conditions]. Its formulation is [dosage form], with typical INDICATION-based dosing regimens. The drug has received FDA approval on [approval date], establishing its regulatory compliance.
Market Dynamics
Therapeutic Class and Competitive Landscape
The drug operates within the [Drug Class], a segment characterized by [market size], projected CAGR of [X]% over the next five years, and a competitive environment featuring [number of competitors]. Key rivals include [Competitor 1], [Competitor 2], and emerging biosimilars or generics. The demand drivers stem from increasing incidence of [related health conditions], evolving treatment guidelines favoring [the drug], and the unmet needs it addresses.
Regulatory and Reimbursement Environment
Through regulatory pathways, the drug benefits from [special designations such as Orphan, Breakthrough Therapy], which can influence market exclusivity and pricing strategies. Reimbursement policies, coverage restrictions, and voice of payers often impact the device’s market penetration. Recent CMS policy shifts aim to promote cost-effective treatments, influencing pricing and utilization.
Prescription Trends and Off-label Use
Data from IQVIA indicates an annual growth rate in prescriptions of approximately [X]% over the past [Y] years, driven by expanding approvals and clinical evidence supporting efficacy. Off-label prescribing constitutes [Z]% of total use, affecting the market size and pricing dynamics.
Price Analysis
Current Pricing
The Wholesale Acquisition Cost (WAC) for NDC 00536-1047 is approximately [$X] per unit. Commercial list prices average [$Y], with variations based on pharmacy benefit managers (PBMs), rebates, and discounts. The Average Selling Price (ASP), factoring in rebates and concessions, reports at approximately [$Z].
Factors Influencing Pricing
- Patent Exclusivity and Market Power: Patent expiry is projected for [year], beyond which generics or biosimilars could introduce price competition.
- Manufacturing and Supply Chain: Costs associated with [complexity of synthesis, biologics manufacturing, etc.] influence baseline price levels.
- Market Penetration and Volume: Higher patient volume can lead to economies of scale, potentially reducing effective prices.
- Regulatory Incentives: Orphan drug designation typically supports premium pricing due to limited alternatives.
Price Projections
Using market trend data and upcoming patent cliffs, projections estimate:
- Short-term (1-2 years): Stabilized pricing, with potential modest increases ([X]% annually) driven by inflation and demand growth.
- Mid-term (3-5 years): Anticipated introduction of biosimilar competitors post-patent expiry, resulting in price reductions of approximately [Y]% to [Z]%.
- Long-term (beyond 5 years): Potential for novel formulations or indications to reinstate higher pricing tiers, contingent on clinical success and regulatory approvals.
These projections depend heavily on competitive entry timing, payer policies, and advancements in therapeutic alternatives.
Market Forecasts
Revenue Projections
Based on current sales volume of [X] units and the prevailing pricing, the estimated annual revenue for the drug is [$X million]. With an anticipated compound annual growth rate (CAGR) of [Y]% over the next five years—accounting for the rise in adoption and potential patent expiry—revenues could reach approximately [$Z million].
Price Sensitivity and Elasticity
Market analyses highlight a relatively elastic demand, with pricing adjustments potentially affecting prescription volumes by up to [X]%. Payer pressure to reduce costs might necessitate discounts of [Y]% to sustain market share.
Geographic and Demographic Factors
Markets in [regions/countries] display differing reimbursement frameworks, impacting pricing strategies. For instance:
- United States: Premium pricing aligns with high healthcare spending but is sensitive to policy changes.
- European Markets: Price negotiations and value-based assessments influence launch prices.
Population demographics, such as aging populations and rise in target conditions, are likely to augment demand.
Strategic Implications
Stakeholders should consider:
- Patent Strategy: Monitoring patent status for timely repositioning or generic entry planning.
- Pricing Negotiations: Engaging payers early to establish favorable reimbursement pathways.
- Market Expansion: Identifying untapped markets with high disease prevalence.
- Cost Management: Optimizing manufacturing processes to sustain healthy margins amid competitive pressures.
Key Takeaways
- Dynamic Market Environment: The drug faces a competitive landscape with impending biosimilar entries and evolving payer policies.
- Pricing Stability and Decline: Short-term stability is expected, but long-term price erosion is likely post-patent expiry, necessitating strategic planning.
- Forecasted Growth: Market demand is projected to grow at a CAGR of [Y]% over five years, driven by increasing disease prevalence and expanded indications.
- Regulatory and Reimbursement Factors: Playing a pivotal role in shaping pricing strategies and market access.
- Opportunity for Differentiation: Incorporating novel formulations, combination therapies, or new indications can sustain pricing power.
FAQs
Q1. When is the patent expiry for NDC 00536-1047, and how will it impact pricing?
A1. The patent is projected to expire in [Year], which typically prompts the entry of biosimilars or generics, leading to significant price reductions of approximately [Y]% over the following 1-2 years.
Q2. How do reimbursement policies influence the drug's market price?
A2. Reimbursement negotiability varies across markets and payers; stricter cost-containment measures often limit allowable prices, pressuring manufacturers to lower list and net prices to maintain market access.
Q3. What are key strategies to maintain market share amid emerging biosimilars?
A3. Strategies include differentiating through clinical data, expanding indications, optimizing patient support programs, and engaging payers early for favorable formulary placement.
Q4. How does clinical evidence support premium pricing?
A4. Robust clinical data demonstrating superior efficacy, safety, or convenience justify higher prices, especially if supported by health economic assessments evidencing cost savings downstream.
Q5. What emerging trends could influence future price projections?
A5. Advances such as personalized medicine, digital health integration, and regulatory incentives for innovative therapies could sustain or elevate pricing, while disruptive biosimilar entries might exert downward pressure.
Conclusion
The market environment for NDC 00536-1047 is characterized by a complex interplay of regulatory, competitive, and economic factors. Short-term stability is likely, but long-term price declines driven by biosimilar competition are anticipated. Strategic positioning, continuous market monitoring, and adaptive pricing strategies will be crucial for stakeholders aiming to maximize value over the product lifecycle.
Sources:
- IQVIA. Prescription and sales data, 2023.
- FDA. Approved Drug Labels and Patent Data, 2023.
- Market Research Future. Biopharmaceutical Market Outlook, 2023.
- CMS Official Policies. Reimbursement and Pricing Frameworks, 2023.
More… ↓
